A
Aravax
Early stage biotechnology company focused on developing the first safe and rapidly effective treatment for peanut allergy
About Aravax
Aravax is a clinical stage biotechnology company focused on developing innovative treatments for food allergies. The company leverages proprietary technology to precisely reset the immune system, enabling it to tolerate allergens without triggering allergic reactions during treatment. Aravax's lead product, PVX108, targets peanut allergies and has successfully completed Phase 1 clinical trials. Currently, Phase 2 trials are underway, recruiting peanut allergic adolescents and children in clinics across Australia and the United States. Founded in May 2015, Aravax emerged from intellectual property developed by Alfred Health and Monash University, with initial investment from the Medical Research Commercialisation Fund (MCRF), managed by Brandon Capital Partners. In January 2024, Aravax closed a Series B funding round, attracting new investors including Novartis Venture Fund, Tenmile, Breakthrough Victoria, Uniseed, and UniSuper. This funding supports the ongoing Phase 2 development of PVX108 and the expansion of Aravax's product pipeline. Aravax primarily serves patients with food allergies, operating within the biotechnology and healthcare markets. The company's business model revolves around the development and commercialization of its proprietary treatments, generating revenue through clinical trials and eventual product sales.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2015
- Headquarters
- Melbourne, Australia
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 86.1/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Intellectual Property, Biotechnology, Spinout, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Feb 2024 | $42M | $168M | Brandon Capital Partners · Novartis Venture Fund · UniSuper · Tenmile | ↗ |
| SERIES BOther financing | Dec 2022 | $20M | $80M | Brandon Capital Partners · Tenmile | ↗ |
Growth signals
Latest recorded traffic for Aravax is 790 monthly website visits, down 39.2% over the last three months. Aravax's team grew 26.7% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Helmedix
Brandon Capital Partners
Innovation Connections
Series A6 investors entered at this stage
Tenmile
Novartis Venture Fund
UniSuper
Uniseed
Breakthrough Victoria- ACAgati Capital
Other known investors1 additional known investor
Monash University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aravax on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aravax’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.